Meningococcal meningitis
MONDO:0018059An acute bacterial disease caused by Neisseria meningitides that presents usually, but not always, with a rash (non blanching petechial or purpuric rash), progressively developing signs of meningitis (fever, vomiting, headache, photophobia, and neck stiffness) and later leading to confusion, delirium and drowsiness. Neck stiffness and photophobia are often absent in infants and young children who may manifest nonspecific signs such as irritability, inconsolable crying, poor feeding, and a bulging fontanel. Meningococcal meningitis may also present as part of early or late onset sepsis in neonates. The disease is potentially fatal. Surviving patients may develop neurological sequelae that include sensorineural hearing loss, seizures, spasticity, attention deficits and intellectual disability.
24 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New meningitis vaccine shows promise for infants in phase 3 trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine (NmCV-5) to protect infants against meningitis, a serious infection of the brain and spine. About 1,325 healthy infants in Mali received either the new vaccine or a standard one at 9 or 15 months old. The goal was to see if the new vaccine works as…
Phase: PHASE3 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:02 UTC
-
Major vaccine study shows meningitis b and pneumonia shots are safe for babies
⭐️ VACCINE ⭐️ CompletedThis study looked at whether giving the meningitis B vaccine (Bexsero) and the pneumonia vaccine (PCV13) along with routine baby shots is safe and works well. About 1,200 healthy infants aged 6 to 12 weeks took part. Researchers checked for side effects like pain, redness, fever,…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
Can a new vaccine safely shield babies from meningitis?
Prevention CompletedThis trial is testing the safety of the Menhycia® vaccine in about 3,000 healthy 3-month-old infants who have not yet received any epidemic meningitis vaccine. The infants will receive three doses of the vaccine at least one month apart, with an optional booster at 12 months of a…
Phase: PHASE4 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Can a new vaccine shield adults from four meningitis strains?
Prevention CompletedThis trial is testing an experimental vaccine called Menhycia, designed to protect against four types of meningococcal bacteria (A, C, Y, and W135) that can cause meningitis and bloodstream infections. The study involves about 1,480 healthy adults aged 18 to 55, who will receive …
Phase: PHASE3 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can a new vaccine shield teens from meningitis?
Prevention CompletedThis trial is testing an experimental vaccine designed to protect against four strains of the bacteria that cause meningococcal meningitis, a serious infection of the brain and spinal cord. The study involves around 840 participants aged 7 to 17, who will receive either the new v…
Phase: PHASE3 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
MRI contrast dye may skew brain scans, study finds
Knowledge-focused CompletedThis study looked at how gadolinium, a dye used in MRI scans, changes the QSM signal in the brain's white matter. 73 patients with inflammatory central nervous system conditions had MRI scans before and after receiving gadolinium. The goal was to measure any differences in the si…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC